AVITA Medical, Inc.
RCELHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, AVITA Medical, Inc. (RCEL) is listed under Medical Devices. At a $321.9M market cap, AVITA Medical, Inc. ranks as a small-cap company within healthcare. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Market Cap
$321.9M
Beta
2.02
P/E (TTM)
—
P/E (Fwd)
-24.07
EPS (TTM)
$-1.44
EPS (Fwd)
$-0.43
ROE
—
ROA
-41.6%
Cash
$11.1M
Total Debt
$48.5M
Free CF
-$13.3M
52W Change
168.6%
Annual Financials
Cash vs Debt
Where RCEL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RCEL finished 113.49% above its 150-day moving average ($5.04) and 129.42% above its 200-day moving average ($4.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RCEL overbought or oversold?
At the September 3, 2026 close, RCEL's RSI(14) was 77.3, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $11.1M in cash, though total debt stands at $48.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$13.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $34.4M (2022) to $71.6M (2025), reflecting a 108% increase over the period.
A beta of 2.02 means RCEL is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AVITA Medical, Inc.'s trajectory.